Calling all healthtech founders: Your data strategy can make or break a deal – UKTN
Bookmark your favorite posts, get daily updates, and enjoy an ad-reduced experience.
Already have an account? Log in
Private equity and venture capital interest in healthtech has surged and activity shows no sign of abating this year.
But some investors are learning the hard way that a glossy pitch deck and polished paperwork are not enough to secure funding, especially when a company’s value hinges on access to sensitive health data, such as biometric scans, genetic profiles, mental health logs and daily activity tracking.
In the wake of high-profile failures, investors and acquirers are taking a more forensic approach to technical due diligence. A promising founder with a bold vision is no longer enough. What matters now is whether the product works, whether it can scale and, crucially, whether underlying data practices stand up to scrutiny.
In high-growth, fast-moving sectors like healthtech, compliance can become a tick-box exercise: present on paper, but poorly embedded in practice. A company might present all the right documents, clear consent terms, GDPR-compliant policies and ISO certifications, but if those are not reflected in day-to-day operations, they won’t withstand scrutiny….
Limited time offer
Save up to 50%.
Now only £39.99 £19.99 / Month*
Access all our premium journalism on any device and see fewer ads.
Cancel subscription renewal anytime.
Already have an account? Log in
Registered in England & Wales at 124 City Roads, London, England, EC1V 2NX
–
Company No. 14998441
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
source
This article was autogenerated from a news feed from CDO TIMES selected high quality news and research sources. There was no editorial review conducted beyond that by CDO TIMES staff. Need help with any of the topics in our articles? Schedule your free CDO TIMES Tech Navigator call today to stay ahead of the curve and gain insider advantages to propel your business!
Already have an account? Log in
Private equity and venture capital interest in healthtech has surged and activity shows no sign of abating this year.
But some investors are learning the hard way that a glossy pitch deck and polished paperwork are not enough to secure funding, especially when a company’s value hinges on access to sensitive health data, such as biometric scans, genetic profiles, mental health logs and daily activity tracking.
In the wake of high-profile failures, investors and acquirers are taking a more forensic approach to technical due diligence. A promising founder with a bold vision is no longer enough. What matters now is whether the product works, whether it can scale and, crucially, whether underlying data practices stand up to scrutiny.
In high-growth, fast-moving sectors like healthtech, compliance can become a tick-box exercise: present on paper, but poorly embedded in practice. A company might present all the right documents, clear consent terms, GDPR-compliant policies and ISO certifications, but if those are not reflected in day-to-day operations, they won’t withstand scrutiny….
Limited time offer
Save up to 50%.
Now only £39.99 £19.99 / Month*
Access all our premium journalism on any device and see fewer ads.
Cancel subscription renewal anytime.
Already have an account? Log in
Registered in England & Wales at 124 City Roads, London, England, EC1V 2NX
–
Company No. 14998441
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
source
This article was autogenerated from a news feed from CDO TIMES selected high quality news and research sources. There was no editorial review conducted beyond that by CDO TIMES staff. Need help with any of the topics in our articles? Schedule your free CDO TIMES Tech Navigator call today to stay ahead of the curve and gain insider advantages to propel your business!
